Larry Lo

1.7k total citations · 1 hit paper
18 papers, 1.2k citations indexed

About

Larry Lo is a scholar working on Surgery, Molecular Biology and Hematology. According to data from OpenAlex, Larry Lo has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 4 papers in Molecular Biology and 4 papers in Hematology. Recurrent topics in Larry Lo's work include IL-33, ST2, and ILC Pathways (3 papers), Iron Metabolism and Disorders (3 papers) and Erythropoietin and Anemia Treatment (3 papers). Larry Lo is often cited by papers focused on IL-33, ST2, and ILC Pathways (3 papers), Iron Metabolism and Disorders (3 papers) and Erythropoietin and Anemia Treatment (3 papers). Larry Lo collaborates with scholars based in United States, Netherlands and Italy. Larry Lo's co-authors include Matt Devalaraja, Michael Davidson, Pablo E. Pérgola, Douglas Kling, Dominic S. Raj, G. Kees Hovingh, Paul M. Ridker, Peter Libby, Florian M.M. Baeres and Milana Ivkovic and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Larry Lo

17 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

2021 433 citations Paul M. Ridker, Matt Devalaraja et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Larry Lo United States	11	565	426	195	177	155	18	1.2k
Danielle M. Carrick United States	23	467 0.8×	248 0.6×	426 2.2×	105 0.6×	110 0.7×	35	1.6k
Karin Fransén Sweden	18	754 1.3×	339 0.8×	153 0.8×	251 1.4×	308 2.0×	35	1.4k
Othmar Ludwiczek Austria	14	250 0.4×	403 0.9×	332 1.7×	184 1.0×	273 1.8×	19	1.3k
K. Lea Sewell United States	16	564 1.0×	588 1.4×	125 0.6×	142 0.8×	415 2.7×	31	1.9k
Davit Manukyan Germany	10	360 0.6×	723 1.7×	214 1.1×	122 0.7×	71 0.5×	17	1.6k
Simon T. Abrams United Kingdom	21	475 0.8×	878 2.1×	482 2.5×	177 1.0×	114 0.7×	44	1.7k
Lemin Wang China	17	434 0.8×	161 0.4×	167 0.9×	263 1.5×	120 0.8×	80	1.0k
Grace M. Thomas United States	12	519 0.9×	970 2.3×	190 1.0×	98 0.6×	160 1.0×	24	1.8k
Estelle S. Harris United States	18	366 0.6×	1000 2.3×	243 1.2×	91 0.5×	269 1.7×	23	1.8k
Alkwin Wanders Sweden	23	367 0.6×	288 0.7×	265 1.4×	582 3.3×	213 1.4×	77	1.5k

Countries citing papers authored by Larry Lo

Since Specialization

Citations

This map shows the geographic impact of Larry Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Lo more than expected).

Fields of papers citing papers by Larry Lo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Lo. The network helps show where Larry Lo may publish in the future.

Co-authorship network of co-authors of Larry Lo

This figure shows the co-authorship network connecting the top 25 collaborators of Larry Lo. A scholar is included among the top collaborators of Larry Lo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry Lo. Larry Lo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Ridker, Paul M., Matt Devalaraja, Florian M.M. Baeres, et al.. (2021). IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 397(10289). 2060–2069. 433 indexed citations breakdown →

Chen, X., M.C. LeCompte, Lawrence Kleinberg, et al.. (2021). Deviation From Consensus Contouring Guidelines Predicts Inferior Local Control After Spine Stereotactic Body Radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 111(3). S101–S101. 1 indexed citations

Chen, X., M.C. LeCompte, Lawrence Kleinberg, et al.. (2021). Immune Checkpoint Inhibitors Improve Survival and Local Control in Patients With Spine Metastasis After Stereotactic Body Radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 111(3). e604–e605. 1 indexed citations

Pérgola, Pablo E., Matt Devalaraja, Steven Fishbane, et al.. (2020). Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Society of Nephrology. 32(1). 211–222. 54 indexed citations

Nowak, Kristen L., Rahul Kakkar, Matt Devalaraja, et al.. (2020). A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2(2). 224–235. 8 indexed citations

Chen, Xuguang, Chengcheng Gui, Jimm Grimm, et al.. (2020). Normal tissue complication probability of vertebral compression fracture after stereotactic body radiotherapy for de novo spine metastasis. Radiotherapy and Oncology. 150. 142–149. 20 indexed citations

Kakkar, Rahul, Larry Lo, Douglas Kling, Matt Devalaraja, & Michael H. Davidson. (2019). Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis. Circulation. 3 indexed citations

Spoto, Belinda, Patrizia Pizzini, Claudia Torino, et al.. (2019). FP379ERYTHROFERRONE PREDICTS MORTALITY AND CARDIOVASCULAR EVENTS IN CKD AND IN HEMODIALYSIS PATIENTS: A TWO COHORTS STUDY. Nephrology Dialysis Transplantation. 34(Supplement_1).

Kakkar, Rahul, Larry Lo, Matt Devalaraja, et al.. (2019). Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study. Journal of Clinical Medicine. 8(4). 523–523. 20 indexed citations

10.

Nugent, Diane J., et al.. (2014). Pharmacokinetics and safety of plasma‐derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia. 21(1). 95–101. 16 indexed citations

11.

Meylan, Françoise, You Young Song, Ivan J. Fuss, et al.. (2011). The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation.. Inflammatory Bowel Diseases. 17(suppl_1). S16–S16. 6 indexed citations

12.

Meylan, Françoise, Ivan J. Fuss, Erin Kahle, et al.. (2010). The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunology. 4(2). 172–185. 115 indexed citations

13.

Migone, Thi-Sau, G. Mani Subramanian, John Zhong, et al.. (2009). Raxibacumab for the Treatment of Inhalational Anthrax. New England Journal of Medicine. 361(2). 135–144. 202 indexed citations

14.

Greco, F. Anthony, Philip Bonomi, Jeffrey Crawford, et al.. (2008). Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 61(1). 82–90. 142 indexed citations

15.

Hotte, Sébastien J., Hal W. Hirte, Eric X. Chen, et al.. (2008). A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 14(11). 3450–3455. 163 indexed citations

16.

Mom, Constantijne H., Stefan Sleijfer, Jourik A. Gietema, et al.. (2006). 202 POSTER Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignacies. European Journal of Cancer Supplements. 4(12). 63–63. 14 indexed citations

17.

Fullerton, Heather J., et al.. (2006). Obstacles to primary stroke prevention in children with sickle cell disease. Neurology. 67(6). 1098–1099. 20 indexed citations

18.

Sleijfer, Stefan, et al.. (2005). A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies.. Data Archiving and Networked Services (DANS). 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact